References
- Price KN, Atluri S, Hsiao JL, et al. Medicare and Medicaid spending trends for immunomodulators prescribed for dermatologic conditions. J Dermatol Treat. 2020;1–5. DOI:10.1080/09546634.2020.1762842
- Prescription drugs (outpatient). Medicare.gov. Available from: https://www.medicare.gov/coverage/prescription-drugs-outpatient
- Cuckler GA, Sisko AM, Poisal JA, et al. National health expenditure projections, 2017–26: despite uncertainty, fundamentals primarily drive spending growth. Health Aff (Millwood). 2018;37(3):482–492.
- Song H, Adamson A, Mostaghimi A. Medicare Part D payments for topical steroids: rising costs and potential savings. JAMA Dermatol. 2017;153(8):755–759.
- Peters JR, Hixon DR, Conner DP, et al. Generic drugs-safe, effective, and affordable. Dermatol Ther. 2009;22(3):229–240.
- Werble C. Health policy brief: Medicare Part B. Health Aff (Millwood). 2017. DOI: 10.1377/hpb20171008.000171